The company recently published new results on its MOBILE study, which found that CGM use increased time in range for people with Type 2 diabetes. New data shows people who stopped using a CGM saw time in range decrease.
Abbott received FDA clearance for an app to pair with its Freestyle Libre 2 glucose monitor. The app lets people get readings directly on their phone without using a reader.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In a wide-ranging interview, Dexcom’s CEO shared more about the company’s push to prove its continuous glucose monitor can be used both for patients with Type 1 and Type 2 diabetes, and how the device-maker is handling a growing number of competitors.
Abbott Laboratories received FDA clearance for its newest continuous glucose monitor, the FreeStyle Libre 2. The product is one of many in a growing market for CGMs.
In an interview at the J.P. Morgan Healthcare Conference in San Francisco earlier this week, the CEO of Dexcom relayed a strong desire to sell CGM systems directly to the consumers with possible pilots this year.
Livongo and Dexcom struck a partnership on Monday that would combine Dexcom’s continuous glucose monitors with Livongo’s software. At the StartUp Health Conference, Livongo President Jennifer Schneider said its work with Dexcom would create a new stream of data for both companies.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Medical device maker Dexcom is partnering with Livongo such that users of Livongo that have diabetes and use Dexcom's continuous glucose monitoring system can sync their data on the Livongo platform.
At the annual meeting of the American Diabetes Association meeting last week, a diabetes epidemiologist compares and contrasts competing CGMs both based on features and accuracy.
On the day that an FDA official exhorts industry to develop interoperable diabetes devices, Medtronic announces that it is teaming up with a nonprofit group to do just that.
Fitabase CEO Aaron Coleman said he sees the integration being particularly useful to researchers looking at how behavioral recommendations in areas like physical activity and sleep can affect glucose levels to create more tailored care plans for diabetic patients.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Medtronic said the company will be rolled into its Diabetes Group to improve its diabetes management capabilities by adding Nutrino's comprehensive food database, food analysis system and nutrition-science expertise.
Months ahead of schedule, FDA clears the use of DexCom's latest continuous glucose monitoring system for patients two and up, freeing them from routine fingerstick calibration.
As a type 1 diabetes patient, I have decided to stay on an open-source insulin delivery solution instead of switching to a hybrid closed-loop insulin delivery system from Medtronic whose FDA approval was widely hailed.
Although DexCom actually was the first to get FDA approval for a continuous glucose monitor with its G5 model last year, it requires finger sticks to calibrate the device.